GlassScriptPhysician profile
Vanessa Johnson
NPI 1912326158
$4,810.14
in general payments reported to CMS, 2019-2025
28 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.44 · 2020: $335 · 2021: $1,026 · 2022: $429 · 2023: $812 · 2024: $1,102 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,064.65 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $935.08 | 2021-2025 | |
| Novo Nordisk INC | $410.30 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $263.74 | 2023-2025 | Repatha, Otezla, Otezla |
| Shield Therapeutics INC | $225.80 | 2024-2025 | |
| Lilly USA, LLC | $223.69 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.94 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $199.12 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $166.35 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $155.54 | 2020-2025 | Farxiga |
| Pfizer INC. | $146.27 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.62 | 2021-2025 | Xifaxan, Relistor |
| Sanofi-Aventis U.S. LLC | $85.73 | 2020-2022 | |
| Ardelyx, INC. | $84.31 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $67.95 | 2021-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $58.73 | 2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Verona Pharma, INC. | $57.67 | 2025 | Ohtuvayre |
| Dexcom, INC. | $48.86 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $47.89 | 2021 | |
| Exact Sciences Corporation | $45.12 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $43.13 | 2023 | Myrbetriq |
| Esperion Therapeutics, INC. | $36.70 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.19 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.05 | 2023 | Uzedy |
| Biohaven Pharmaceuticals, INC. | $16.53 | 2021 | |
| Allergan, INC. | $16.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.28 | 2023 | Eliquis |
| Mylan Specialty L.P. | $12.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.